Life Science Investing Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
Life Science Investing Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
Life Science Investing Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
